-- 根據週一提交給印度證券交易所的文件顯示，Rossari Biotech（NSE：ROSSARI，BOM：543213）第四財季歸屬於股東的合併利潤從去年同期的3.444億盧比躍升至4.597億盧比。 該公司股價在近期交易中下跌近6%。 截至3月31日的季度，每股收益從去年同期的6.21盧比增至8.29盧比。 文件顯示，這家化學公司的營業收入年增，從58億盧比增加至68.5億盧比。 Rossari Biotech董事會建議派發截至3月31日財年的末期股息，每股0.50盧比。
Related Articles
Research
Morgan Stanley Upgrades Garmin to Equalweight From Underweight, Adjusts PT to $252 From $195
Garmin (GRMN) has an average rating of hold and mean price target of $261.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GRMN
Research
Morgan Stanley Upgrades Phillips 66 to Overweight From Equalweight, Adjusts PT to $174 From $147
Phillips 66 (PSX) has an average rating of overweight and mean price target of $182.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$PSX
Research
Morgan Stanley Downgrades CSX to Underweight From Equalweight, Price Target is $30
CSX (CSX) has an average rating of overweight and mean price target of $45.84, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$CSX